New drug approvals for 2022: Synthesis and clinical applications
Medicinal Research Reviews · 2023
DOI: 10.1002/med.21976 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2023. Verfasst von Shuo Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 160 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific and Technological Project of Henan Province.
Abstract (Originalsprache)
The U.S. Food and Drug Administration has approved a total of 37 new drugs in 2022, which are composed of 20 chemical entities and 17 biologics. In particular, 20 chemical entities, including 17 small molecule drugs, 1 radiotherapy, and 2 diagnostic agents, provide privileged scaffolds, breakthrough clinical benefits, and a new mechanism of action for the discovery of more potent clinical candidates. The structure‐based drug development with clear targets and fragment‐based drug development with privileged scaffolds have always been the important modules in the field of drug discovery, which could easily bypass the patent protection and bring about improved biological activity. Therefore, we summarized the relevant valuable information about clinical application, mechanism of action, and chemical synthesis of 17 newly approved small molecule drugs in 2022. We hope this timely and comprehensive review could bring about creative and elegant inspiration on the synthetic methodologies and mechanism of action for the discovery of new drugs with novel chemical scaffolds and extended clinical indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Zhengzhou University, Zhengzhou, China.
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
- Department of Obstetrics and Gynecology, Zhengzhou Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Hong-Min Liu
Förderung
- National Natural Science Foundation of China
- Scientific and Technological Project of Henan Province
Zitieren
APA
Yuan, S., Shen, D. D., Jia, R., Sun, J. S., Song, J., & Liu, H. M. (2023). New drug approvals for 2022: Synthesis and clinical applications. Medicinal Research Reviews. https://doi.org/10.1002/med.21976
Vancouver
Yuan S, Shen DD, Jia R, Sun JS, Song J, Liu HM. New drug approvals for 2022: Synthesis and clinical applications. Medicinal Research Reviews. 2023. doi:10.1002/med.21976
BibTeX
@article{Yuan2023,
author = {Yuan, Shuo and Shen, Dan-Dan and Jia, Rui and Sun, Ju-Shan and Song, Jian and Liu, Hong-Min},
title = {New drug approvals for 2022: Synthesis and clinical applications},
journal = {Medicinal Research Reviews},
year = {2023},
doi = {10.1002/med.21976}
}
EUVIMED